Viatris | VTRS - Selling And Administration Expenses



Viatris reported $928.7M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Adcock Ingram Holdings ZAR 1.05B 50.17M Dec/2024
Celltrion KRW 276.8B 58.09B Mar/2025
Cspc Pharmaceutical CNY 1.89B 347.81M Mar/2025
Dianthus Therapeutics USD 8.87M 2.04M Jun/2025
Divis Laboratories Ltd 3.4B 10M Jun/2025
Kangmei Pharma CNY 259.36M 49.8M Jun/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 12.94M 5.87M Dec/2024
Neuren Pharmaceuticals AUD 2.33M 47K Dec/2024
Organigram Holdings CAD 25.49M 8.3M Jun/2025
Pharma Mar EUR 14.68M 1M Jun/2025
Qiagen NV USD 148.74M 10.8M Jun/2025
Sartorius EUR 225.2M 6.7M Jun/2025
Sino Biopharmaceutical CNY 5.31B 1.54B Dec/2024
Tilray USD 72.38M 4.99M Nov/2024
Viatris USD 928.7M 111.2M Jun/2025
Zz Pientze Pharmaceu -171290000 342.58M Jun/2025